Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Receivables (2022 - 2024)

Avidity Biosciences' Receivables history spans 3 years, with the latest figure at $9.4 million for Q4 2024.

  • For Q4 2024, Receivables rose 754.93% year-over-year to $9.4 million; the TTM value through Dec 2024 reached $9.4 million, up 754.93%, while the annual FY2024 figure was $9.4 million, 754.93% up from the prior year.
  • Receivables reached $9.4 million in Q4 2024 per RNA's latest filing, up from $1.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $9.4 million in Q4 2024 to a low of $1.1 million in Q4 2023.
  • Average Receivables over 3 years is $3.1 million, with a median of $1.6 million recorded in 2024.
  • Peak YoY movement for Receivables: tumbled 53.26% in 2023, then skyrocketed 754.93% in 2024.
  • A 3-year view of Receivables shows it stood at $2.4 million in 2022, then crashed by 53.26% to $1.1 million in 2023, then surged by 754.93% to $9.4 million in 2024.
  • Per Business Quant, the three most recent readings for RNA's Receivables are $9.4 million (Q4 2024), $1.6 million (Q1 2024), and $1.1 million (Q4 2023).